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Abstract
 .Two proteases, denoted b- and g-secretase, process the b-amyloid peptide precursor APP to yield the Ab peptides
involved in Alzheimer’s disease. A third protein, a-secretase, cleaves APP near the middle of the Ab sequence and thus
prevents Ab formation. These enzymes have defied identification. Because of its similarity to the systems of mammalian
cells the yeast secretory system has provided important clues for finding mammalian processing enzymes. When expressed
in Saccharomyces cere˝isiae APP is processed by enzymes that possess the specificity of the a-secretases of multicellular
organisms. APP processing by a-secretases occurred in sec1 and sec7 mutants, in which transport to the cell surface or to
the vacuole is blocked, but not in sec17 or sec18 mutants, in which transport from the endoplasmic reticulum to the Golgi
is blocked. Neutralization of the vacuole by NH Cl did not block a-secretase action. The time course of processing of a4
pro-a-factor leader-APP chimera showed that processing by Kex2 protease, a Golgi protease that removes the leader,
preceded processing by a-secretase. Deletions of the genes encoding the GPI-linked aspartyl proteases Yap3 and Mkc7
decreased a-secretase activity by 56 and 29%, respectively; whereas, the double deletion decreased the activity by 86%. An
altered form of APP-695, in which glutamine replaced Lys-612 at the cleavage site, is cleaved by Yap3 at 5% the rate of the
 .wild-type APP. Mkc7 protease cleaved APP K612Q at about 20% the rate of wild-type APP. The simplest interpretation
of these results is that Yap3 and Mkc7 proteases are a-secretases which act on APP in the late Golgi. They suggest that
GPI-linked aspartyl proteases should be investigated as candidate secretases in mammalian tissues. q 1997 Elsevier Science
B.V.
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1. Introduction
 .The b-amyloid peptide precursor b-APP iso-
forms comprise a family of transmembrane proteins
that contain the amino acid sequences of the 40–42-
) Corresponding author. Fax: q1 718 4945287.
residue Ab peptides found in the cerebral amyloid
deposits of Alzheimer’s disease victims. Unidentified
proteases cleave b-APP at three sites in or near its
transmembrane sequence. Two of these cleavages at
.the b- and g-secretase sites respectively yield the
amino and carboxyl termini of Ab. The a-secretase
cleavage occurs near the middle of the Ab sequence
0167-4889r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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and thus prevents the formation of the amyloid pep-
tides. The molecular biology and metabolism of b-
w xAPP has been reviewed by Haass and Selkoe 1 .
a-Secretase converts b-APP from a cell-associated
w xform to a secreted form 2 . b-APP resembles certain
other transmembrane proteins in this property. Pro-
w xteases also release transforming growth factor-a 3 ,
w xcolony-stimulating factor 1 4 , and angiotensin-con-
w xverting enzyme 5 , among other membrane-anchored
w xproteins 6 . These processing enzymes remain
unidentified; however, some recent evidence suggests
w xthat they share functional similarities 7 .
The processing proteases of the secretory system
have not readily yielded their identities, because they
act in the environments of specific compartments and
because when their isolation is attempted they be-
come masked by other proteases released in cell
lysates. The prohormone convertase that processes
w xpro-insulin 8 was discovered only after the charac-
terization of a yeast protease, Kex2 endopeptidase
 .Kex2p , which possessed the same substrate se-
w xquence specificity 9 . Sequence similarity searches
and PCR amplification of the homologous mRNAs
then revealed the coding sequences of the convertases
for pro-insulin as well as for pro-opiomelanocortin
w x w x10 and other neuropeptide pro-hormones 11 .
When transfected with a b-APP expression plas-
mid, certain yeast strains synthesize b-APP, translo-
cate it to membranes, and secrete its ecto-domain
w x12,13 . The yeast protease cleaves b-APP at the
w xsame residue as mammalian a-secretase 12,13 . In
this report we characterize the time-course of b-APP
processing in various yeast strains and compare the
rates of processing of wild-type b-APP and b-APP
containing a mutation at the cleavage site. From these
results we conclude that yeast a-secretase is a dis-
crete enzyme that can act in the late Golgi, a com-
partment that is equivalent to a site of action of the
w xmammalian enzyme 15,16 . We confirm the finding
 .Robert Fuller, private communication that Yap3p
and Mkc7p each possess a-secretase activity and we
compared the relative activities of the two enzymes
for an APP substrate altered at the cleavage site.
2. Methods and materials
2.1. Materials
2.1.1. Antisera
Antiserum R57 and monoclonal antibodies 6E10
and 4G8 were described in the previous publication
w x12 . Their epitopes are indicated in Fig. 1. Rabbit
antiserum R104 was raised to native human secreted
 .APP sAPP expressed in Sf9 cells infected with a
recombinant baculovirus that expressed APP. Its epi-
 .tope s have not been determined.
2.1.2. Yeast strains and cell culture
Yeast strains used in this study are listed in Table
1. Yeast transformation was carried out using an
w xelectroporation procedure 17 . Transformants were
selected by growth on solid synthetic minimal medium
 .without uracil containing 1 M sorbitol . Transformed
cells were precultured in UrayrLeuy selective media
 .4% glucose at 308C. The cells were then either
 .grown in YPD 2% glucose at 308C for APP expres-
Table 1
Yeast strains
Name Genotype Source or Ref.
w xJSC310 MATa leu2 ura3-52 prb1-1122 pep4-3 prc1-407 GAP-ADR1::G418 12
w xDS7 MATa MFa1ra2::LEU2 ade2 his3 leu2 trp1 ura3 31
w xYBAD1 MATa YAP3::HIS3 MFa1ra2::LEU2 ade2 his3 leu2 trp1 ura3 31
RSY269rsec17-1 MATa ura3-52 his4-619 R. Schekman
RSY271rsec18-1 MATa ura3-52 his4-619 R. Schekman
RSY299rsec7-1 MATa ade2 his3-11 leu2-3, 112 trp-1-1 ura3-1 R. Schekman
RSY782rsec1-1 MATa ura3-52 his4-619 R. Schekman
M200-6ck MATa KEX2::URA3 ura3 ade1 il˝3 sst1 sst2 M. Whiteway
DE9 MATa MFa1ra2::LEU2 YAP3::HIS3 ade2 his3 leu2 trp1 ura3 MKC7::TRP1 This study
DE12 MATa MFa1ra2::LEU2 MKC7::TRP1 ade2 his3 leu2 trp1 ura3 This study
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sion or in methionine-deficient synthetic medium
 y .  .Met SM from Bio101, Vista, CA containing 3%
glucose for radiolabeling. Temperature-sensitive mu-
 . tants sec mutants were grown at 228C permissive
. temperature and assayed at 378C non-permissive
.temperature .
2.2. Methods
2.2.1. Clone and mutant constructions
The construction of expression shuttle vector
pBS24.1 harboring the APP-695 gene with the full-
 .length pro-a-factor leader pBS6a , Fig. 1 has been
w xdescribed previously 12 . In the construct, the in-
serted gene is controlled by the glucose-repressible
ADH2rGAPDH hybrid promoter.
The substitution of Gln for Lys-612 was achieved
by site-directed mutagenesis using PCR and the UDG
w xcloning method devised by Rashtchian et al. 18 .
SphI-linearized plasmid pBS6a was used as the tem-
plate. The internal mutagenic primers used were the
 Xfollowing: CP1b reverse, 5 CACCAAUUGAUGAU-
X.  XGAACTTCATA3 and CP2b forward, 5 CAUCAA
X .CAAUUGGUGUTCTTTGCAG3 . The flanking
 Xprimers were: CP1a forward, 5 CUACUACUACU-
X.AGACGGAGGAGATCTCTGAAGTG and CP2b
 Xreverse, 5 CAUCAUCAUCAUGGCGTCGACTCA-
X.CTAGTTC-TG3 . The mismatched position in each
oligonucleotide is underlined. The two PCR frag-
ments amplified from the APP-695 gene were treated
 .with uracil DNA glycosylase UDG , annealed to
 .plasmid pAMP2 Gibco-BRL and introduced into
MAX EFFICIENCY DH5 competent cells Gibco-
.BRL . Subsequently, the APP-695 mutant was sub-
cloned into pBS6a by insertion of the pAMP2
Bgl II–Sal I restriction fragment into the Bgl II and
Sal I sites of pBS6a . The sequence of the inserted
fragment was verified by double-stranded sequencing
of the plasmid templates dsDNA cycle sequencing
.system, Gibco-BRL .
To confirm the absence of an intact YAP3 gene in
strain YBAD1, a Southern analysis of the genomic
DNA from the cells was conducted. The DNA was
isolated following the method of Philippsen et al.
w x19 , and hybridized to a probe corresponding to a
region contained in the YAP3 gene but not in the
homologous BAR1 gene. The sequence of the probe
was 5X-CGTCAGGTTACCGCTAAAGGAAGC-3X
 . w x1578–1601 of the YAP3 sequence 14 . DNA from
the parent strain DS7 was run as a positive control.
2.2.2. MKC7 deletion
The MKC7 gene was disrupted by the TRP1 aux-
otrophic marker. The gene was PCR-amplified from
yeast chromosomal DNA, using primers that intro-
duced a 5X SphI site and a 3X SmaI site. The PCR
 .product was ligated into pGEM-T Promega and its
identity was confirmed by restriction fragment analy-
sis. The TRP1 gene from YDp-W kindly donated by
.Rolf Sternglanz, Stony Brook, NY, USA was intro-
duced as a Sal IrBamHI fragment to replace the
680-bp SalIrBamHI fragment in the MKC7 gene.
This plasmid was digested with P˝uII and trans-
fected into yeast strains YBAD1 and DS7 by electro-
poration. Colonies that grew on Trpy medium were
analyzed by PCR to confirm the presence of the
TRP1 insertion into MKC7.
2.2.3. Protein radiolabeling
Yeast cells were first grown in LeurUra-deficient
 .synthetic medium 4% glucose at 308C, and then in
 y .the synthetic medium free of methionine Met SM
with 3% glucose at 308C until early-to-mid exponen-
 .tial phase OD s0.5–1 . The cells were collected600
by centrifugation, resuspended in fresh MetySM con-
 .taining 0.05% glucose 3 OD unitsrml , and incu-600
bated at 308C for 2 h to induce APP expression.
w35 xLabeling was initiated with 25 mCi of Tran S
 .label ICN per OD unit cells. After pulse-labeling600
for 5–10 min, labeled proteins were chased for the
indicated durations by addition of 1 mM cysteine, 5
mM methionine, 1 mM ammonium sulfate and 2%
glucose. One-ml aliquots were collected into sodium
 .azide 10 mM on ice, and cell lysis and immuno-
precipitation were performed as previously described
w x12 . Both polyclonal rabbit anti-C-terminus antibody
 .  .R57 and anti-sAPP R104 were used to immuno-
precipitate the labeled APP from the cell lysate. The
final immunocomplex immobilized on protein A
 .beads Pierce Inc. was resuspended in 30 ml 2=SDS
sample buffer and subjected to Tricine–SDS–PAGE
 .7r11% discontinuous slab gel described by Schag-
w xger and Jagow 20 . The gels were dried and exposed
to Kodak X-Omat AR films at room temperature for
appropriate periods of time. Densitometric analysis of
the autoradiogram was carried out with a scanning
( )W. Zhang et al.rBiochimica et Biophysica Acta 1359 1997 110–122 113
 .densitometer Mirror 600 color scanner and the com-
 .puter application IPLab Gel Signal Analytics . The
quantification of a-secretase activity in various yeast
 .mutants Table 2, Fig. 5 was performed on dried
gels through the use of a Fujifilm BAS 1500 phos-
phorimager.
2.2.4. Effects of NH Cl on a-secretase acti˝ity4
 .A culture of RSY271-pBS6a sec18 was grown
at 228C overnight in methionine-dropout SM 4%
.glucose . The mid-log-phase yeast cells were then
incubated in MetySM containing 0.05% glucose for
1.5 h at 358C to induce both expression of APP
fusion protein and blockage of protein transport at the
 .endoplasmic reticulum. The cells 3 OD unitsrml600
were then grown in ammonium-free minimal medium
 .pH 7.7 with 1% proline as the nitrogen source
 . w xMV-pro 21 for 30 min at 358C. The cells were
subsequently labeled for 30 min at 358C, followed by
treatment with 0.4 M NaCl or 0.4 M NH Cl for 204
min at the same temperature. The reversion of the
blockage of the secretory pathway was initiated by
the return of the labeled cells to 228C, and they were
chased for 3.5 h in the presence of the same concen-
trations of the two salts. Cell lysates were subjected
to immunoprecipitation with R57 and Tricine–PAGE,
and the gel was fixed, impregnated with EN3HANCE
 .New England Nuclear , dried and exposed to film at
y808C for appropriate times.
2.2.5. In˝ertase assay
Sec mutants transformed with pBS6a were grown
 .overnight in YPD 5% glucose at 248C to an OD600
of 0.9–2.6. Cells were transferred to fresh YPD with
 .0.1% glucose 0.8 OD unitsrml and incubated at600
37 or 248C for 1.5 h to induce invertase expression.
 .An aliquot 1 ml was then removed and treated with
 .sodium azide final concentration 10 mM at 08C.
 .Another aliquot 1 ml from the culture at 378C was
further incubated at 228C for 3 h in the presence of 1
mg of glucose and 0.1 mg of cycloheximide to
measure the secretion of accumulated intracellular
invertase. Samples from each condition were washed
with 10 mM sodium azide and resuspended in 0.5 ml
of the same solution. To assay internal invertase,
spheroplast lysates were prepared following the mod-
w xified procedure of Franzusoff et al. 22 . N-Ethyl-
maleimide was added to eliminate residual DTT.
External and internal invertases were assayed at 378C
 .by the glucose oxidase and peroxidase system Sigma
w xas described by Goldstein and Lampen 23 . One unit
of activity is 1 mmol of glucose released per min.
2.2.6. Glycosylation studies
 .Yeast cells RSY271rpBS6a; sec18 at early- to
mid-log phase in methionine-deficient SM 3% glu-
.cose were divided into two equal portions. Cells
from one portion were resuspended in the same
 . medium 3 OD units per ml with tunicamycin 10600
.mgrml . The culture was preincubated for 30 min at
258C to deplete the intracellular pool of dolichol-lin-
ked oligosaccharides, and again subdivided into two
equal portions. Cells were resuspended in the
MetySM with 0.05% glucose under the same condi-
tions. One portion was shifted to 378C, while the
other was kept at 258C. After 1 h at the indicated
temperatures, cells were labeled for 40 min, and
analyzed by immunoprecipitation with R57, as de-
Table 2
Invertase secretion and accumulation by sec mutants
aStrain Unitsrmg dry weight
b cExternal Internal External % release External Internal
 .  .   .  .90 min, 378C 90 min, 378C 90 min, 378C 90 min, 258C 90 min, 258C
.“3 h, 258C
RSY271r18-1 0.11 2.94 1.93 62.0 1.66 0.60
RSY782r1-1 0.37 3.05 1.35 32.1 1.47 1.10
RSY299r7-1 0.10 2.13 1.63 71.8 1.45 0.62
a Units of invertase activity are mmol of glucose released per min.
b Cells were incubated at 258C in the presence of 0.1 mgrml cycloheximide as described in the text.
c  .% releases Ext yExt rInt =100.378C “ 258C 378C 378C
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scribed above. A control experiment without tuni-
camycin was similarly conducted. The effectiveness
of tunicamycin on inhibition of N-linked glycosyla-
tion was confirmed by assaying a-factor secretion in
the presence of tunicamycin as described by Julius et
w xal. 24 .
The Endo H digestion of radiolabeled APP was
conducted according to the protocol by Genzyme
Corp. R57-immunoprecipitated 35S-labeled APP from
RSY271rpBS6a were removed from protein A beads
 .by heating in 1% SDS 20 ml in a boiling water
bath, diluted by the addition of 180 ml 50 mM
 .sodium citrate pH 5.8 , heated again for 1 min, and
clarified by centrifugation. The supernatant was incu-
bated in the presence of Endo H 50 mUrml; Gen-
.zyme at 378C for 5 h. The sample was dried using a
 .centrifugal concentrator Savant Speed-Vac , redis-
 .solved in 1= electrophoresis sample buffer 30 ml ,
heated in a boiling water bath for 2 min, and ana-
lyzed by Tricine–SDS–PAGE.
3. Results
3.1. Time course of APP processing
w xPrevious studies 12,13 had shown that yeast con-
tains a functional homolog of mammalian a-secre-
tase, which cleaves b-APP at lysine-612, 13 residues
before the beginning of the transmembrane sequence
 .Fig. 1 . To determine the time-course of processing
of b-APP-695, a culture of JSC310 transfected with
 . w35 xpBS6a Fig. 1 was pulse-labeled with S methion-
ine, and at timed intervals b-APP and its cleavage
products were immunoprecipitated with antiserum
 .R57 specific for the C-terminal 7 residues or R104
 .raised to the ecto-domain . The immunoprecipitated
proteins were separated by SDS–PAGE and visual-
ized by autoradiography. b-APP-695 initially ap-
peared as a single band of apparent mass about 105
 .kDa Fig. 2A,B . The 7-kDa C-terminal fragment
 .CTF, Fig. 2A and the 90-kDa extracellular domain
 .sAPP, Fig. 2B generated by a-secretase began to
appear after 10 min, as full-length APP coordinately
disappeared. Two isoforms of sAPP appearing as a
.double band around 90 kDa in Fig. 2B were im-
munoprecipitated from the cell lysate in addition to
full-length b-APP. The smaller form lacked the 6E10
Fig. 1. Map of plasmid pBS6a and its pro-a-factor-leader-APP-
 .695 insert. The b-peptide sequence hatched box extends into
 .the transmembrane TM sequence. Polyclonal antibody R57
recognizes the seven residues at the COOH terminus. mAb 6E10
and mAb 4G8 recognize epitopes adjacent to the a-secretase
 .cleavage site S . The underlined Lys-612 was changed to Gln in
 .plasmid pBS6a KrQ . The dark and stippled boxes, respec-
tively, denote the secretory signal sequence and the pro-a-factor
leader.
 .epitope near the C-terminus of sAPP data not shown .
This form must have resulted from a subsequent
cleavage of the a-secretase product, because R57 did
not immunoprecipitate a C-terminal fragment com-
plementary to it. The ca. 48-kDa translation product
formed by cleavage in the vicinity of residue 300.
The pBS6a vector encodes a fusion protein in
which APP-695 is preceded by the yeast pheromone
 .pre-pro-a-factor leader Fig. 1 ; however, in this
experiment the fusion protein was not observed. The
processing of the pro-a-factor leader by Kex2p oc-
w xcurs in less than 5 min 24 , and had been completed
before the cells were lysed at the first chase time
point. In other experiments at higher levels of expres-
 .sion or lower temperatures e.g. Fig. 4 , the fusion
protein was observed.
The time course of a-secretase cleavage was much
slower than that of Kex2p, and it was biphasic Fig.
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Fig. 2. Time-course of pulse-labeled APP cleavage by a-secre-
tase. JSC310 transfected by pBS6a was labeled for 10 min with
w35 xS methionine and cysteine. At the indicated intervals the pep-
 .tides were immunoprecipitated with either R57 panel A or
 .R104 panel B and subjected to electrophoresis and autoradiog-
raphy. Panel C: densitometric analysis of the autoradiograms.
CTF, C-terminal fragment; sAPP, secreted APP.
.2C . The rapid phase has a half-time of about 18 min,
while the slow phase proceeds with a half-time of
about 2 h. The C-terminal fragments are relatively
stable in JSC310, which lacks the major vacuolar
w xproteases A and B 12 .
The secretory form of APP accumulated within the
 .cells over a period of 2 h Fig. 2B . As in the
previous study little sAPP appeared in the medium.
In cells expressing APP for 2 days, about one-half of
the sAPP becomes bound to the cell surface in a form
that can be released by treatment with an alkaline
w xthiol solution 12 ; however, in 4 h of radiolabelling
very little 35S-labeled sAPP could be released by this
 .procedure data not shown .
3.2. Localization of a-secretase acti˝ity
Several steps of the yeast secretory process have
been defined by conditional mutants that block secre-
w x  .tion 22,25 . Strain RSY271 sec18 contains a tem-
perature-sensitive mutation that blocks ER to Golgi
 .transport; whereas, in strains RSY299 sec7 and
 .RSY782 sec1 mutations block transport from the
Golgi to secretory vesicles, and from these vesicles to
the plasma membrane, respectively. The sec7 muta-
w xtion also blocks transport to the vacuole 26 . To
further identify the compartment in which a-secre-
tase acts, we studied the processing of APP in these
strains at permissive and non-permissive tempera-
tures.
To confirm that our isolates each contained a sec
mutation, we measured their capacities to synthesize
and secrete invertase at 25 and 378C. Each strain
synthesized invertase at both 25 and 378C, but could
 .secrete the enzyme only at 258C Table 2 . In addi-
w xtion, the mutants were thermoreversible 22 ; upon
return to the permissive temperature in the presence
of a protein synthesis inhibitor, the accumulated in-
vertase was secreted. This result indicates that, in all
of the mutants, vesicular transport was not irre-
versibly damaged by the treatment.
Each strain was transfected with pBS6a and was
pulse-labeled at either 25 or 378C, and the extent of
processing after 30 min was determined by the phos-
phorimaging procedure. The ratio of the radioactivity
of the C-terminal fragment after a 30-min chase to
that of full-length APP at zero time was calculated
 .Table 3 . In sec1 and sec18 strains about 3% of the
radioactive label originally incorporated into APP
appeared in the C-terminal fragment after 30 min at
 .258C Table 3 . Correcting for its relative methionine
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 .content 0.2 about 15% of the initial APP was
cleaved to the C-terminal fragment after 30 min.
About 80–90% of the initial APP was turned over
during the period. Other processes, particularly, vac-
uolar proteolysis, degrade both APP and the C-termi-
nal fragment and lower the yield of the a-secretase
product. A small fraction of APP escaped a-secretase
 .and appeared on the cell surface result not shown .
At 378C, a-secretase processing does not occur in the
sec18 mutant; however, processing is not much af-
fected in the sec1 strain, or in DS7, a strain that
contains a wild-type secretory system. The small
change in the yield of C-terminal fragment in DS7
indicates that a-secretase activity possesses a low
temperature coefficient.
The sec7 mutant in repeated experiments yielded
higher extents of conversion to the C-terminal frag-
ment. Part of the explanation for this behavior is that
the sec7 mutation, which blocks transport to the
vacuole, prevents turnover of the C-terminal frag-
ment. However, sec7 also affects other steps in tran-
sit through the Golgi. Because of these complexities,
and because this sec7 strain is not isogenic with the
other strains, direct quantitative comparisons are not
warranted. In summary the results in Table 3 show
that the sec18 mutation blocks a-secretase action;
whereas, sec7 and sec1 mutations do not signifi-
cantly affect its action.
To confirm that a-secretase resides in the secre-
tory system rather than the vacuole, we investigated
APP cleavage in cells that had been treated with 0.4
M NH Cl, a concentration at which the proton gradi-4
ent is eliminated, and the transport of proteins to the
w xvacuole is blocked 27,28 . Since high concentrations
Fig. 3. APP cleavage by a-secretase in NH Cl-treated cells.4
 .RSY271 sec18 harboring pBS6a was incubated at 358C for 1.5
h to block protein transport at ER. The cells were then pulse-
w35 xlabeled with Tran S label at 358C and treated with 0.4 M
 .NH Cl or 0.4 M NaCl as a control at 358C followed by4
incubation in 228C waterbath to reverse the blockage of the
secretory pathway. The APP processing was analyzed by
immunoprecipitation of APP and its C-fragment, Tricine–PAGE
and fluorography.
of NH Cl interfered with the radio-labeling of pro-4
teins in yeast, we first labeled the proteins of sec18-
pBS6a at 358C, at which temperature the labeled
proteins were retained in the ER, and subsequently
treated the cells with 0.4 M NH Cl at the same4
 .temperature. As seen from Fig. 3 left two lanes ,
under these conditions only APP fusion proteins ex-
isted, and no mature APP could be observed, which
would require the transport of the fusion protein from
the ER to the late Golgi to be processed by Kex2p.
Table 3
Processing of b-APP in temperature-sensitive sec mutants a
Strain Process blocked CTFrAPP Ratio of 37r258Co
258C 378C
RSY271rsec18-1 ER“Golgi 0.035 0.000 0.0
RSY299rsec7-1 Golgi“secretory vesicles 0.100 0.067 0.7
RSY782rsec1-1 sec. ves.“plasma membrane 0.027 0.028 1.0
DS7 none 0.036 0.025 0.7
a  .  .  .Sec mutants transformed by pBS6a 3 OD unitsrml were incubated in SM free of methionine 0.05% glucose at permissive 258C600
 .or non-permissive 378C temperatures for 2 h to induce APP expression and block the secretory pathway. The cultures were then
radiolabeled and assayed as described in Section 2.2. Each PAGE gel was subjected to phosphorimaging, and from these values was
 . calculated the ratio of the radioactivity of the C-terminal fragment at a chase time of 30 min to the radioactivity of full-length APP at 0
.chase time . The ratio of the amount of C-terminal fragment formed at 378C to that formed at 258C was then calculated.
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Upon shifting to 228C, however, protein transport
was restored, which was indicated by the conversion
of the fusion protein to mature APP Fig. 3, right two
.lanes . NH Cl did not prevent the production of the4
7-kDa C-terminal fragment and, accordingly, the a-
secretase cleavage of APP. The vacuole, neverthe-
less, might be involved in other processing activities
of APP. More mature APP remained intact in
NH Cl-treated cells than in NaCl-treated cells, proba-4
bly because NH Cl hampered the transport of mature4
APP to the vacuole andror the processing of APP in
the vacuole. To confirm that the NH Cl treatment4
eliminated the vacuolar proton gradient we showed
 .data not presented that it prevented the pH-depen-
w xdent vacuolar uptake of quinacrine 29 .
3.3. Glycosylation of pro-a-APP
APP possesses two N-linked glycosylation sites to
which polysaccharides could be attached in mam-
w xmalian cells 30 . To determine whether these sites
are glycosylated in yeast and whether their glycosyla-
tion affects the ability of a-secretase to cleave APP,
we employed two independent methods of analysis.
In untreated sec18rpBS6a labeled at 258C, two
predominant R57 immunoreactive full-length APP-
containing proteins appeared Fig. 4, lane 1, bands A
.and B . When the cells were labeled in the presence
of tunicamycin, the predominant protein starred band
.in lane 2 possessed a mass about 7 kDa less than
band A and 8 kDa greater than band B. When the
cells were labeled at 378C to impose a secretion
block in the transport from the ER to the Golgi, a
single R57-immunoreactive species was detected in
 .the presence of tunicamycin lane 5 , which was 7
kDa smaller than the glycosylated APP fusion protein
 .retained in the ER lane 4 , and had a mass identical
to that of the starred-band at 258C. Since at 378C the
fusion protein cannot encounter Kex2p, the starred-
bands correspond to the unglycosylated APP fusion
protein. Band A is then the glycosylated fusion pro-
tein and band B is the full-length APP free of a-
leader. Since the a-leader region of pro-a-factor has
three N-linked mannose-rich oligosaccharide chains
which account for about 7 kDa of its molecular mass
w x24 , the 7 kDa reduction of the molecular mass of
tunicamycin-treated APP fusion protein must reflect
the removal of all of those oligosaccharide chains
Fig. 4. Effect of glycosylation on a-secretase action. Strain
 .RSY271 sec18 transfected with pBS6a was labeled for 1 h
w35 x with S methionine and cysteine in either the absence lanes
.  .1,3,4,6 or presence lanes 2,5 of tunicamycin at either 258C
 .  .lanes 1–3 or 378C lanes 4–6 . Peptides containing the C-termi-
nal epitope were immunoprecipitated with R57 and analyzed as
described in Fig. 2A. Before electrophoresis, portions of the
immunoprecipitate from untreated cells were digested with endo-
glycosidase H, as described in Section 2.2. The starred bands are
discussed in the text.
from the a-leader portion of the fusion protein. Thus
APP must not be subject to glycosyl modification in
yeast. Indeed, both the mature a-leader-cleaved APP
molecules with or without tunicamycin treatment have
the same apparent molecular masses compare bands
.B, lanes 1 and 2 .
To confirm this conclusion, the material immuno-
precipitated from sec18rpBS6a cells was exhaus-
tively digested with the enzyme endoglycosidase H
 .endo H to remove N-linked carbohydrate chains
w xfrom the peptide backbone 31 . This treatment
yielded two APP-related species similar to those
formed in tunicamycin-treated cells, except that the
larger species corresponding to the APP-a-leader fu-
sion protein migrated slightly slower than the fusion
 .protein starred-band from tunicamycin-treated cells
 .Fig. 4, lanes 3 and 5 . A comparison of the relative
densities of the bands in lanes 1 and 2 revealed that
tunicamycin retarded the conversion of the fusion
protein to mature APP. Tunicamycin induced a simi-
lar accumulation of unglycosylated pro-a-factor and
( )W. Zhang et al.rBiochimica et Biophysica Acta 1359 1997 110–122118
w xinhibition of a-factor maturation 24 . Thus efficient
Kex2p cleavage requires glycosylation of pro-a-fac-
tor. The reduced amount of the 7-kDa C-terminal
a-secretase product observed in lane 2 probably re-
sulted from the reduced rate of transit of the fusion
protein. In contrast, APP processing by yeast a-
secretase does not require the glycosylation of APP.
3.4. APP processing in yap3, mkc7 and kex2 mutants
The aspartyl protease, Yap3p, can process pro-a-
w xfactor precursors at monobasic cleavage sites 14,32 .
To investigate the role of Yap3p in the processing of
APP, we expressed pBS6a in a yap3 null mutant,
w35 xYBAD1. The cells were labeled with S methionine
and chased for 30 min. The extent of a-secretase
cleavage of APP was then determined by immuno-
precipitation of APP and the C-terminal fragment
 .CTF followed by PAGE, autoradiography and phos-
phorimaging analysis. The extent of CTF formation
 .Fig. 5. Processing of wild-type APP-695 and APP K612Q in
yeast strains bearing deletions in YAP3 and MKC7. Cells were
w35 xlabeled for 10 min with Tran S label and chased for 30 min at
308C. APP and C-terminal fragments were immunoprecipitated
with R57 and subjected to SDS–PAGE. The radioactivity was
quantified by phosphorimaging, and the fraction of radioactivity
 .in APP all forms at ts0 that appeared in CTF at 30 min was
calculated. The error bars indicate the standard deviations of two
or three independent experiments. Strains: DS7, YAP3q MKC7 q;
DE12, YAP3q MKC7 y; DE9, YAP3y MKC7 y; YBAD, YAP3y
MKC7 q.
in the yap3 mutant was about 44% of that of the DS7
 .parent strain Fig. 5 .
Mkc7 protease, an enzyme closely related to
Yap3p, can also process pro-a-factor at basic residue
pairs. When APP was expressed in the mkc7 null
 .mutant DE12 Fig. 5 the extent of CTF formation
was about 70% of the DS7 parent. In DE9, the
mkc7ryap3 double mutant, the extent of CTF forma-
 .tion was about 14% of the DS7 parent Fig. 5 . We
compared the yields of secreted proteins from DE9
and DS7 by PAGE of proteins precipitated from the
35  .media from S-labeled cultures results not shown .
Although there were some differences in the intensi-
ties of a few of the approximately 18 bands resolved,
there was no systematic decrease in the yield of
secreted proteins from DE9. Thus we concluded that
neither deletion introduced a general defect into the
secretory system.
w xTo confirm the results of Zhang et al. 13 that
a-secretase is not an alternative activity of Kex2p, we
expressed pBS6a in a kex2 mutant, M200-6C. As
 .was previously reported, we found results not shown
that in the absence of Kex2p the fusion protein was
extensively cleaved to yield the C-terminal fragment.
3.5. Effect of pepstatin A on yeast a-secretase
Pepstatin A inhibits, to varying degrees, many
aspartyl proteases in vitro as well as in tissue ex-
w xplants 33 . At 100 mM concentration it inhibited the
cleavage of lipotropin by purified Yap3p to the extent
w xof 85% 34 . Pepstatin A should inhibit the cleavage
of APP by Yap3p, if the cleavage occurs in a low pH
compartment accessible to the pentapeptide inhibitor.
We attempted to inhibit the a-secretase cleavage of
APP in intact yeast cells without success. We then
prepared spheroplasts of DS7 expressing APP6a ,
incubated them with pepstatin A, and performed the
pulse-labeling assay for a-secretase activity. When
 .performed at pH 5.1 Table 4 , pH 6.6, or pH 7.4
 .results not shown , the assay revealed no inhibition
by pepstatin A at concentrations up to 80 mM. In all
experiments the extent of a-secretase cleavage was
only one-third of that observed in intact cells. This
probably indicates that the spheroplasting procedure
damaged the cells to some extent. The significance of
these results are discussed in a later section.
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Table 4
Effect of pepstatin A on a-secretase activity in DS7
 .Pepstatin A mM CTFrAPP Relative CTFrAPPo o
0 0.009 1.0
50 0.010 1.1
80 0.018 1.9
Cells from yeast strain DS7 expressing APP6a were converted to
w xspheroplasts using lyticase as previously described 12 . Hypo-
osmotic shock induced nearly complete lysis of the preparation.
After incubation for 30 min with pepstatin A in spheroplast
medium plus 50 mM Na citrate, pH 5.1, the spheroplasts were
w35 xpulse-labeled with Tran S label for 10 min and chased for 30
min in the presence or absence of the inhibitor as indicated. The
labeled APP and its C-terminal fragments were immunoprecipi-
tated with R57, resolved by SDS–PAGE, and analyzed by phos-
phorimaging. CTFrAPP is the ratio of the amount of CTF aftero
 .30 min chase to the amount of APP all forms at 0 chase time.
3.6. a-Secretase processing of APP altered at the
clea˝age site
Mutagenesis studies have indicated that mam-
malian a-secretase can cleave the peptide bond be-
tween the 13th and 12th residues N-terminal to the
transmembrane sequence, with little specificity for
w xthe nature of the 13th residue 35,36 . Other studies
suggest that a-secretase may cleave at any of several
residues in the vicinity if Lys-612 is not available
w x37 . We assayed the specificity of yeast a-secretase
 .by determining its activity on APP-695 K612Q ,
which was produced by introducing a point mutation
into vector pBS6a .
When transfected into the parent strain DS7, APP-
 .695 K612Q yielded about 15% of the amount of
 .CTF from wild-type APP-695 Fig. 5 . To determine
the effect of the lysyl-glutaminyl alteration upon the
activities of Yap3p and Mkc7p, we analyzed the
extent of CTF formation in single and double dele-
 .tion mutants transfected with APP-695 K612Q . The
yields of CTF from the mutant APP were small;
consequently standard deviations of our measure-
 .ments were relatively large Fig. 5 . Given this uncer-
tainty, Yap3p appeared to be more specific for Lys-
612 than Mkc7p. Yap3p cleaved the mutant APP at
about 5% of the rate of wild-type APP; whereas,
Mkc7 protease cleaved the mutant APP at about 20%
of the rate of wild-type APP.
We did not determine whether Yap3p and Mkc7p
actually cleaved the mutant APP at Gln-612. Al-
though the phosphoimager bands from the Lys-612
and Gln-612 cleavage products appeared to be the
same size, we were unlikely to discern size difference
of less than five residues. We were able to immuno-
precipitate a small amount of sAPP from the medium
and to identify it with mAb 6E10, whose epitope
includes the four amino acid residues amino-terminal
 .to Lys-612 not shown . Thus, in any case the cleav-
age occurred very close to Lys-612.
4. Discussion
The substantial deficit in a-secretase activity in
the mkc7 and yap3 deletion mutants suggests that
these proteases are the major yeast a-secretases, al-
though the possibility exists that each activates a
zymogen, which is the true a-secretase. The
mkc7ryap3 deletions do not affect the secretion of
most endogenous proteins. We have not yet demon-
strated that purified Yap3p can cleave APP at Lys
612; however, that yeast a-secretase prefers to cleave
APP at a lysyl rather than a glutaminyl residue agrees
with the specificity of Yap3p, which has been shown
to cleave other substrates at single lysyl residues
w x14,32 . The specificity of Mkc7p has not been re-
ported. Our results indicate that it is less highly
 .specific for lysyl residues, since APP K612Q is
cleaved to a somewhat greater extent in the yap3
deletion than in the yap3rmkc7 double deletion.
We initially suggested that yeast a-secretase was
not likely to be a vacuolar enzyme, because the bulk
of sAPP was found either in the medium or associ-
w xated with extracellular membranes 12 . We demon-
strated here that a-secretase processing proceeds in
cells treated with 0.4 M NH Cl, which both blocks4
transport to the vacuole and increases the vacuolar
w xpH. Other investigators 27–29 found that when
yeast cells were treated with weak amines,
bafilomycin A , or the proton ionophore carbonyl1
cyanide m-chlorophenyl hydrazone, the vacuoles were
not acidified and did not accumulate the fluorescent
amine quinacrine. More importantly, under these con-
ditions the vacuolar enzymes, proteinase A and car-
boxypeptidase Y, were secreted rather than being
translocated to their normal destination in the vac-
uole. These results suggest that in the absence of the
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proton gradient proteins cannot be transported to the
vacuole. We found that the treatment with 0.4 M
NH Cl prevented the accumulation of quinacrine in4
vacuoles, but it did not diminish the activity of
w xa-secretase processing of APP. Stevens et al. 26
reported that sec7 mutants failed to transport
carboxypeptidase Y to the vacuole; whereas, we found
that a-secretase processing of APP is not diminished
in a sec7 mutant. In addition we also found that
a-secretase processing occurred as rapidly in JSC310,
which lacks proteases A, B and C, as in strains with
wild-type vacuolar proteases. Although a-secretase
cleavage does not occur in the vacuole, both un-
cleaved APP and the C-terminal fragment turn over
more rapidly in WT cells than in vacuolar protease-
deficient cells; therefore, they probably follow the
default pathway for membrane proteins to the vac-
w xuole 38 .
Both Yap3p and Mkc7p have been shown to be
anchored to membranes through glycosyl phos-
phatidylinositol moieties, and they are thought to be
w xprimarily localized to the plasma membrane 39 . We
found that APP is rapidly processed in sec7 and sec1
mutants, which block transport of APP to the plasma
membrane. This result is susceptible to multiple inter-
pretations. The sec mutations may trap both APP and
Yap3p in the same compartment, where they might
not normally have time to interact. Alternatively, in
the sec1 and sec7 mutants at the non-permissive
temperature another protease that normally resides in
the late Golgi or in secretory vesicles may have
enough time to cleave the trapped APP. Although
these conjectures may not be invalid for the sec7
mutant results, where increased APP processing was
observed, they are not consistent with the sec1 mu-
tant results, where blockage of transport to the cell
surface did not increase the extent of proteolysis over
that observed in the DS7 control strain. The lack of
inhibition of APP processing by peptstatin A is fur-
ther evidence against the cell surface being the major
site for APP processing by Yap3p.
The failure of pepstatin A to inhibit Yap3prMkc7p
in vivo is not inconsistent with the reported character-
istics of the inhibitor. Although it inhibits certain
aspartyl proteases, notably pepsin and cathepsin D, at
pH 4 with K values in the nanomolar range, itI
w xinhibits them poorly at a pH above 6 40 . The pH of
the compartment where a-secretase acts is unknown,
but it is likely to resemble the pH of the mammalian
w xGolgi which is about 6.45 41 . Pepstatin A is a
w xrelatively poor inhibitor of Yap3p 34 ; it inhibits
purified Yap3p 85% at 100 mM, pH 4.6; its effect on
Mkc7p has not been reported. Furthermore, if Yap3p
cleaved APP in an acidic environment, one would
have expected that NH Cl treatment would decrease4
the rate when it neutralized the acidic compartments;
however, we found that the cleavage rate was not
affected by NH Cl treatment. Whether inhibitory4
concentrations of pepstatin A can accumulate in the
Golgi is unknown. For these reasons pepstatin A
cannot be considered to be a general inhibitor of
aspartyl proteases in vivo.
We propose the following model for the time-
course of APP processing in yeast. Pro-a-APP is
rapidly transported to the late Golgi, where it is
cleaved by Kex2p within 5 min. Yap3prMkc7p then
release sAPP within 18 min, in a later Golgi compart-
ment. The minor fraction of sAPP formed in the
slower phase may represent APP that avoided cleav-
age in the Golgi and escaped to cell surface, from
which it may be recycled to the Golgi.
Since a-secretase cleavage of APP proceeds more
slowly than the constitutive secretion of a-factor or
invertase, APP must be selectively retained in the late
Golgi. The transmembrane a-factor processing en-
zymes Kex2p, Kex1p, and dipeptidyl aminopeptidase
are retained in the late Golgi by sequences in their
cytoplasmic domains that may interact with clathrin
w xadaptor proteins 42 . APP possesses a mammalian
clathrin adaptor sequence in its cytoplasmic domain,
which facilitates its processing in an endocytic com-
w xpartment 43 . Possibly this sequence interacts with
the yeast clathrin structure on the late Golgi.
As the APP-fusion protein passes through the ER
and Golgi, its pro-a-leader sequence is glycosylated,
like the endogenous pro-a-factor itself; however, the
yeast enzyme does not appear to recognize the APP
N-linked glycosylation sites. APP shares this property
with several other mammalian proteins, for example,
hepatitis B surface antigen, which, when expressed in
w xyeast, is not glycosylated 44,45 . In CHO cells, only
one of APP’s potential N-linked glycosylation sites is
w xmodified 30 . In yeast, a-secretase processing does
not require glycosylation of APP.
The function of yeast a-secretase remains to be
identified. Although both Yap3p and Mkc7p were
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discovered by their ability to suppress kex2 muta-
tions, their primary physiological functions may be
related to their abilities to release membrane-associ-
ated proteins. We know of no other example in yeast
where a membrane-associated protease releases the
ecto-domain of a transmembrane protein. The juxta-
position of the active site of a membrane-bound
protease and a membrane-bound substrate must intro-
duce topological constraints that increase the speci-
ficity of cleavage.
In mammalian cells, a-secretase acts both on the
cell surface and in a late-stage secretory compart-
w xment. CHO cells release cell-surface APP 33,43 ;
whereas, in PC12 cells, as in S. cere˝isiae, a-secre-
tase cleaves APP in a secretory compartment beyond
w xthe medial Golgi 15,16,46 . In MDCK cells, sAPP
can be produced by cleavage both within a secretory
w xcompartment and on the cell surface 47 .
Inhibitor studies of mammalian a-secretases have
yielded equivocal results. Some of these studies have
suggested that a-secretase may be a zinc metallopro-
w xtease 7,48 ; whereas, others have shown no effects of
w xzinc chelators 16 . In CHO cells the extensive cleav-
age of APP on the plasma membrane is sensitive to
w xmetalloprotease inhibitors 48 ; however, it was not
shown that this cleavage occurs at the a-secretase
site. The protease that releases tumor necrosis factor
from its precursor has recently been proved to be a
w xzinc metalloprotease 49,50 ; however, it differs from
a-secretase in its peptide bond specificity and cleave
distance from the plasma membrane.
It may be that mammalian cells contain several
w xtypes of a-secretase. Cordell and co-workers 37
suggest that this would best explain the observed
cleavage patterns of APP mutants. Such a redundancy
has been reported among the pro-hormone conver-
tases that process pro-opiomelanocortin in the pitu-
itary. One pair of enzymes, PC1 and PC2, are subtil-
w xisin-related serine proteases 10 ; whereas a third
enzyme, PCE, is a Yap3-related aspartyl protease
w x51 .
APP-like proteins have been found in all tested
w xmammals and even in Drosophila 52 ; however, no
homologous protein has yet been reported in yeast.
Yeast a-secretase thus may possess a function differ-
ent from its mammalian counterpart. Other mam-
malian transmembrane proteins besides APP undergo
proteolysis to secrete active ecto-domains. In mam-
malian cells certain growth factors, growth factor
receptors, cytokines, cell adhesion molecules and
ecto-enzymes exist in transmembrane and soluble
extracellular forms. Yeast secretes a number of other
enzymes into its periplasm as well as mannan, a
glycoprotein component of its outer membrane
w x53,54 . Perhaps a-secretase processes one of these
proteins. Alternatively, a-secretase might release the
ecto-domain of a transmembrane signal transduction
protein, thereby antagonizing its action. The identifi-
cation of Yap3p and Mkc7p as secretases suggests
the existence of a new biochemical process in yeast.
It further suggests that mammalian secretases may be
GPI-linked aspartyl proteases.
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